Sotalol

Sotalol
Clinical data
Trade names	Betapace, Sorine, Sotylize, others
AHFS/Drugs.com	Monograph
MedlinePlus	a693010
License data	US DailyMed: Sotalol;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
Drug class	Beta blocker
ATC code	C07AA07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	90–100%
Metabolism	Not metabolized
Elimination half-life	12 hours
Excretion	Kidney ; Mammary gland (In lactating individuals)
Identifiers
	IUPAC name (RS)-N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide;
CAS Number	3930-20-9 ;
PubChem CID	5253;
IUPHAR/BPS	7297;
DrugBank	DB00489 ;
ChemSpider	5063 ;
UNII	A6D97U294I;
KEGG	D08525 ;
ChEMBL	ChEMBL471 ;
CompTox Dashboard (EPA)	DTXSID0023589 ;
Chemical and physical data
Formula	C12H20N2O3S
Molar mass	272.36 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=S(=O)(Nc1ccc(cc1)C(O)CNC(C)C)C;
	InChI InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 ; Key:ZBMZVLHSJCTVON-UHFFFAOYSA-N ;
	(verify)

Sotalol, sold under the brand name Betapace among others, is a medication used to treat and prevent abnormal heart rhythms.^[1] Evidence does not support a decreased risk of death with long term use.^[1] It is taken by mouth or given by injection into a vein.^[1]

Common side effects include a slow heart rate, chest pain, low blood pressure, feeling tired, dizziness, shortness of breath, problems seeing, vomiting, and swelling.^[1] Other serious side effects may include QT prolongation, heart failure, or bronchospasm.^[3] Sotalol is a non-selective β-adrenergic receptor blocker which has both class II and class III antiarrhythmic properties.^[1]

Sotalol was first described in 1964 and came into medical use in 1974.^[4] It is available as a generic medication.^[3] In 2020, it was the 296th most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[5]^[6]

^ ^a ^b ^c ^d ^e ^f "Sotalol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
^ ^a ^b ^c ^d Cite error: The named reference fda2009 was invoked but never defined (see the help page).
^ ^a ^b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 108. ISBN 9780857113382.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 9783527607495.
^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
^ "Sotalol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

[AHFS2019-1] ^ ^a ^b ^c ^d ^e ^f "Sotalol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.

[fda2009-2] Cite error: The named reference fda2009 was invoked but never defined (see the help page).

[BNF76-3] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 108. ISBN 9780857113382.

[4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 9783527607495.

[5] "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.

[6] "Sotalol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

[1]

[2]

[3]

[4]

[5]

[6]